Presentation
PDC*line Pharma is a clinical-stage spin-off of the French Blood Bank (EFS) that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human phase Ib in melanoma, PDC*line Pharma has initiated a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*Neo).
Contact
Address
PDC*line Pharma SAS, EFS, 29 avenue du Maquis du Grésivaudan, 38701 La Tronche, France
Website
Targeted indications : Lung cancer, Head and neck cancers, Skin cancer